抗坏血酸对维持性血液透析患者血清Hepcidin的影响  

Effect of Ascorbic Acid on Serum Hepcidin in Maintenance Hemodialysis Patients

作　　者：刘景慧[1] 徐书婷 彭小梅[1] 刘芸芳[1] 韦献峰[1] 曾剑锋[3] 张文欣[1] 

机构地区：[1]广西壮族自治区人民医院肾内科,南宁530021 [2]广西壮族自治区人民医院检验科,南宁530021 [3]广西中医药大学

出　　处：《中国中西医结合肾病杂志》2013年第10期875-877,共3页Chinese Journal of Integrated Traditional and Western Nephrology

基　　金：广西壮族自治区卫生厅计划项目(No.Z2012275)

摘　　要：目的:观察抗坏血酸对维持性血液透析(MHD)患者血清铁调素(Hepcidin)的影响。方法:选择符合条件的MHD患者60例,分为治疗组和对照组各30例。治疗组每日口服抗坏血酸300 mg,共12周,对照组不服用抗坏血酸及其他抗氧化剂。检测两组实验前后血清Hepcidin、血红蛋白(Hb)、白蛋白(Alb)、C反应蛋白(CRP)、铁蛋白(SF)、白细胞介素(IL-6)等相关指标,比较两组指标的变化。结果:两组实验前各项指标差异无统计学意义。治疗组口服抗坏血酸12周后,血CRP、IL-6水平下降,差异有统计学意义(P<0.05);Hepcidin、SF、Hb、Alb差异无统计学意义。对照组实验前后各项试验指标差异无统计学意义。结论:口服抗坏血酸在一定程度上降低MHD患者血CRP、IL-6水平,但对Hepcidin未产生显著影响。Objective：the Effects of ascorbic acid on serum hepcidin in maintenance hemodialysis（MHD） patients.Methods：Sixty patients were divided into experiment group and control group.Patients in the experiment group took 300 mg ascorbic acid orally per day for 12 weeks.Control group treated without ascorbic acid and any other antioxidant.Before and after experiment,serum hepcidin,IL-6,c-reactive protein（CRP）,ferritin,hemoglobin,Alb were determined.Results：There was no significant difference between two groups before experiment.12 weeks later,the levels of IL-6,CRP were significant decreased in experiment group.Hepcidin remained unchanged in both groups.Conclusion：Ascorbic acid orally 300mg per day did not change serum hepcidin significantly in MHD patients.

关 键 词：铁调素 抗坏血酸 微炎症状态 肾性贫血 

分 类 号：R692.5[医药卫生—泌尿科学]